• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    3/19/24 5:34:06 PM ET
    $ABEO
    $AQST
    $ENVB
    $ETAO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABEO alert in real time by email

    Gainers

    • Etao International Co (NASDAQ:ETAO) stock rose 249.4% to $0.5 during Tuesday's after-market session. The company's market cap stands at $51.1 million.
    • Taysha Gene Therapies (NASDAQ:TSHA) shares moved upwards by 29.36% to $2.91. The market value of their outstanding shares is at $544.1 million. The company's, Q4 earnings came out today.
    • Moleculin Biotech (NASDAQ:MBRX) shares increased by 14.54% to $0.6. The market value of their outstanding shares is at $20.0 million.
    • Turnstone Biologics (NASDAQ:TSBX) stock moved upwards by 11.5% to $3.49. The market value of their outstanding shares is at $80.5 million.
    • Enveric Biosciences (NASDAQ:ENVB) shares rose 8.4% to $1.29. The company's market cap stands at $6.9 million.
    • SCWorx (NASDAQ:WORX) shares increased by 8.37% to $3.04. The market value of their outstanding shares is at $3.6 million.

    Losers

    • Aquestive Therapeutics (NASDAQ:AQST) stock declined by 11.4% to $4.73 during Tuesday's after-market session. The company's market cap stands at $346.7 million.
    • Trxade Health (NASDAQ:MEDS) stock decreased by 8.85% to $18.85. The company's market cap stands at $22.7 million.
    • Ontrak (NASDAQ:OTRK) shares declined by 8.41% to $0.4. The market value of their outstanding shares is at $11.1 million.
    • Virpax Pharmaceuticals (NASDAQ:VRPX) shares declined by 7.59% to $3.9. The company's market cap stands at $4.5 million.
    • Longeveron (NASDAQ:LGVN) shares decreased by 6.91% to $0.42. The company's market cap stands at $10.5 million.
    • Abeona Therapeutics (NASDAQ:ABEO) shares declined by 6.74% to $7.06. The company's market cap stands at $187.2 million. As per the press release, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABEO
    $AQST
    $ENVB
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Taysha Gene Therapies Inc.
    $TSHA
    10/21/2025$13.00Strong Buy
    Raymond James
    Taysha Gene Therapies Inc.
    $TSHA
    7/11/2025$8.00Buy
    BofA Securities
    Moleculin Biotech Inc.
    $MBRX
    6/9/2025$4.00Buy
    H.C. Wainwright
    Aquestive Therapeutics Inc.
    $AQST
    6/2/2025$7.00Outperform
    Oppenheimer
    Abeona Therapeutics Inc.
    $ABEO
    6/2/2025$19.00Outperform
    Oppenheimer
    Abeona Therapeutics Inc.
    $ABEO
    3/5/2025$16.00Outperform
    Oppenheimer
    Moleculin Biotech Inc.
    $MBRX
    2/12/2025Buy → Hold
    Maxim Group
    Turnstone Biologics Corp.
    $TSBX
    2/5/2025$3.75 → $0.40Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Goldan Keith A.

    4 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/7/26 8:47:16 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Goldan Keith A.

    3 - ABEONA THERAPEUTICS INC. (0000318306) (Issuer)

    4/7/26 8:45:26 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lehr Paul T

    4 - Longeveron Inc. (0001721484) (Issuer)

    4/3/26 5:00:18 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Taysha Gene Therapies with a new price target

    Raymond James initiated coverage of Taysha Gene Therapies with a rating of Strong Buy and set a new price target of $13.00

    10/21/25 7:22:35 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BofA Securities initiated coverage on Taysha Gene Therapies with a new price target

    BofA Securities initiated coverage of Taysha Gene Therapies with a rating of Buy and set a new price target of $8.00

    7/11/25 8:16:08 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright resumed coverage on Moleculin Biotech with a new price target

    H.C. Wainwright resumed coverage of Moleculin Biotech with a rating of Buy and set a new price target of $4.00

    6/9/25 7:52:11 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Moleculin Releases Next CEO Corner Segment Highlighting Annamycin's Non-Cardiotoxic Profile

    Access the Moleculin CEO Corner here HOUSTON, April 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today announced it has released the next segment on its CEO Corner, a platform featuring Walter Klemp, Chief Executive Officer. In this segment, Mr. Klemp highlights the differentiated safety profile of Annamycin, emphasizing its lack of cardiotoxicity which is a significant limitation associated with traditional anthracyclines such as doxorubicin. Annamycin was specifically designed to avoid cardiac damage, and has demonstrated this advantage across preclinical and clinical studies. This non-cardiotoxic profile could expand treatment opt

    4/7/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On March 31, 2026, the Compensation Committee of Abeona's Board of Directors granted restricted stock equity awards as a material inducement to employment to four individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 8,400 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the grant date, such that the

    4/6/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    SEC Filings

    View All

    SCWorx Corp. filed SEC Form 8-K: Other Events

    8-K - SCWorx Corp. (0001674227) (Filer)

    4/7/26 3:00:51 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Abeona Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - ABEONA THERAPEUTICS INC. (0000318306) (Filer)

    4/7/26 8:35:30 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Enveric Biosciences Inc.

    PRE 14A - Enveric Biosciences, Inc. (0000890821) (Filer)

    4/3/26 5:05:48 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Foster Jonathan P. covered exercise/tax liability with 1,715 shares, bought $100,000 worth of shares (270,270 units at $0.37) and converted options into 7,039 shares, increasing direct ownership by 2,298% to 287,587 units (SEC Form 4)

    4 - Moleculin Biotech, Inc. (0001659617) (Issuer)

    6/23/25 4:35:31 PM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    Abeona Therapeutics® Announces Appointment of Keith A. Goldan to its Board of Directors

    CLEVELAND, April 07, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO) today announced the appointment of Keith A. Goldan as a new independent member to its Board of Directors, effective as of April 1, 2026. Mr. Goldan will also serve as Chairman of Abeona's Audit Committee. Mr. Goldan brings more than two decades of financial leadership experience across publicly traded commercial-stage biotechnology and specialty pharmaceutical companies. His appointment to the Board of Directors reflects Abeona's continued focus on strengthening its leadership team to advance both strategic and financial objectives. "On behalf of the Board, we are delighted to welcome Keith to Abeona," sa

    4/7/26 8:30:00 AM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

    Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr

    3/20/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

    Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi

    2/18/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Abeona Therapeutics Inc.

    SC 13G/A - ABEONA THERAPEUTICS INC. (0000318306) (Subject)

    11/14/24 7:56:28 PM ET
    $ABEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABEO
    $AQST
    $ENVB
    $ETAO
    Financials

    Live finance-specific insights

    View All

    Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026

    Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AML HOUSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). "With the MIRACLE trial rapidly progressing and the first MIRACLE i

    3/19/26 8:36:00 AM ET
    $MBRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

    Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of ≥3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026 Maintained favorable tolerability profile with no treatment-related SAEs or DLTs in REVEAL Phase 1/2 and REVEAL pivotal trials as of March 2026 data cutoff; longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in Q2 2026 Reached written alignment with FDA on proposed PPQ

    3/19/26 8:00:00 AM ET
    $TSHA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

    On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II may serve as foundation for a Biologics License Application (BLA) submission for full approval for HLHS, if results demonstrate sufficient evidence of efficacyClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, March 17

    3/17/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care